Risk perception, attitudes, and quality of life in a multicomponent benzodiazepine deprescription strategy
Metadatos
Mostrar el registro completo del ítemAutor
Ferrer López, Ingrid; Olry de Labry-Lima, Antonio; Gutiérrez Valencia, Alicia; García Bermúdez, Encarnación; Atienza Martín, Francisco Javier; García-Delgado Morente, Amalia; Murillo Fernández, María Dolores; Sánchez Cañete, Yolanda; Bermúdez-Tamayo, ClaraEditorial
Elsevier
Materia
Benzodiazepine Deprescription Inappropriate prescribing
Fecha
2025-12Referencia bibliográfica
Ferrer López, I., Olry de Labry-Lima, A., Gutiérrez-Valencia, A., García Bermúdez, E., Atienza Martín, F., Morente, A. G.-D., Murillo Fernández, M. D., Sánchez Cañete, Y., & Bermúdez-Tamayo, C. (2025). Risk perception, attitudes, and quality of life in a multicomponent benzodiazepine deprescription strategy. Exploratory Research in Clinical and Social Pharmacy, 20(100666), 100666. https://doi.org/10.1016/j.rcsop.2025.100666
Resumen
Background: Multicomponent strategies can reduce benzodiazepine (BZD) use. BenzoStopJuntos (Spanish for
“Stop Benzos Together”), a multidisciplinary deprescribing programme of the Andalusian Health Service, supports patients to taper/stop BZD through education, behavioral support, and non-pharmacological alternatives.
We evaluated whether early changes (6 months) in risk perception and attitudes—and secondarily, quality of
life—were associated with long-term discontinuation of BZD.
Methods: In a quasi-experimental pre–post study in two primary care centres (Seville, Spain; n = 243), the
intervention included patient education, tapering support, and alternatives for anxiety/insomnia delivered by a
multidisciplinary team. Primary outcomes were (a) short-term (6-month) changes in risk perception and attitudes and (b) long-term BZD discontinuation over 5.5 years; the secondary outcome was quality of life (WONCA/
COOP), monitored to detect potential harms. Multivariable logistic regression examined whether 6-month
changes in beliefs/attitudes predicted subsequent discontinuation, adjusting for sociodemographic and clinical
factors.
Results: BZD discontinuation increased from 31.3 % at 6 months to 40.7 % at 5.5 years. Participants who
considered BZD safe long-term were more likely to continue use (OR = 2.0; 95 % CI: 1.6–2.6). Fears of worsened
anxiety/sleep strongly predicted persistence (OR = 4.7; 95 % CI: 3.6–6.1). Prior intermittent vs continuous use
favored discontinuation (OR = 4.9; 95 % CI: 3.7–6.5). Quality of life improved in emotional, social, and physical
domains, with no deterioration observed during follow-up.
Conclusions: Tailored education and behavioral strategies changed risk perceptions and attitudes, which in turn
facilitated sustained BZD discontinuation without adverse effects on quality of life. Addressing patient beliefs and
encouraging intermittent use patterns may enhance deprescribing success.





